Genetic clustering of European cancer patients indicates that opioid-mediated pain relief is independent of ancestry

A. Galvan, T. Fladvad, F. Skorpen, X. Gao, P. Klepstad, S. Kaasa, T. A. Dragani

Research output: Contribution to journalArticle

Abstract

The European Pharmacogenetic Opioid Study (EPOS) of a large series of European cancer patients treated with opioids was carried out to assess the influence of genetics on cancer pain relief. As response to opioid therapy was associated with the patients country of origin, we tested whether population stratification might represent a confounding factor in the analysis of genetic control of response to opioid therapy. From the whole EPOS series representing 2294 patients genotypes for 379 single-nucleotide polymorphisms (SNPs), we extracted 117 autosomal SNPs with minor allele frequency

Original languageEnglish
Pages (from-to)412-416
Number of pages5
JournalPharmacogenomics Journal
Volume12
Issue number5
DOIs
Publication statusPublished - Oct 2012

Keywords

  • opioids
  • pharmacogenomics
  • polygenic diseases
  • single-nucleotide polymorphisms

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Fingerprint Dive into the research topics of 'Genetic clustering of European cancer patients indicates that opioid-mediated pain relief is independent of ancestry'. Together they form a unique fingerprint.

Cite this